Phytochemistry and Pharmacological Applications of Citrullus Colocynthis

Citrullus colocynthis, commonly known as bitter apple, is a drought-adapted member of the Cucurbitaceae family whose fruits, seeds, leaves and roots have been used in traditional medicine across Africa, Asia and the Middle East. Phytochemical studies reveal a rich repertoire of bioactive secondary metabolites, most notably cucurbitacins, triterpene glycosides, flavonoids, phenolic acids and essential fatty acids. These compounds confer a broad spectrum of biological activities, including antioxidant, anti-inflammatory, antimicrobial, antidiabetic and anticancer effects. Modern analytical techniques—such as high-performance liquid chromatography, gas chromatography–mass spectrometry and high-resolution mass spectrometry—have enabled detailed chemical profiling, uncovering novel cucurbitacin derivatives, oxygenated monoterpenes and complex phenolic matrices. Pharmacologically, C. colocynthis extracts modulate key signalling pathways (NFκB, NFAT, AP-1), inhibit tumour cell proliferation, enhance free-radical scavenging, and suppress microbial growth, while exhibiting acceptable safety margins in normal cell models. Beyond therapeutic prospects, this species is gaining attention for functional food applications, nutraceutical formulation and eco-friendly nanoparticle synthesis, highlighting its global significance as a versatile phytopharmaceutical resource.

Research from Nature Portfolio

Recent studies have employed high-resolution liquid chromatography–quadrupole time-of-flight mass spectrometry to characterise ethyl acetate fruit extracts, identifying over twenty cucurbitacin and triterpene derivatives. These isolates demonstrated dose-dependent cytotoxicity against pancreatic (MIA PaCa-2) and epidermoid carcinoma (A431) cell lines, while sparing healthy cells. Antioxidant capacity assessed via DPPH radical scavenging reached levels comparable to benchmark polyphenols. Molecular docking and molecular dynamics simulations have revealed that specific cucurbitacin diols engage the ATP-binding cleft of epidermal growth factor receptor, providing a mechanistic rationale for their anti-tumour efficacy and opening avenues for structure-guided optimisation of natural anticancer agents.

Phytochemistry and Pharmacological Applications of Citrullus Colocynthis publication trend

The graph below shows the total number of articles in phytochemistry and pharmacological applications of citrullus colocynthis across all publications each year (not limited to Nature Index journals).

Technical terms

Cucurbitacins: Highly oxygenated tetracyclic triterpenes known for cytotoxic and anti-inflammatory properties.

HPLC/QTOF/MS: High-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry, used for comprehensive metabolite profiling.

DPPH assay: A spectrophotometric test measuring radical scavenging activity to quantify antioxidant potential.

Antiproliferative activity: The capacity of a substance to inhibit cell division and growth, particularly in cancer models.

Immunomodulation: The alteration of immune responses, including cytokine production and lymphocyte activation pathways.

References

1. Citrullus colocynthis (bitter apple): bioactive compounds, nutritional profile, nutraceutical properties and potential food applications: a review. Food Production, Processing and Nutrition (2023).
2. Citrullus colocynthis (L.) Schrad (Bitter Apple Fruit): Promising Traditional Uses, Pharmacological Effects, Aspects, and Potential Applications. Frontiers in Pharmacology (2022).
3. Anticancer activity, phytochemical investigation and molecular docking insights of Citrullus colocynthis (L.) fruits. Scientific Reports (2023).
4. Antiproliferative and immunomodulative potential of Citrullus colocynthis and its bioactive compounds in human lymphocytes and lung cells. Journal of Ethnopharmacology (2024).
5. Gas chromatography – Mass spectrometry (GC-MS) profiling reveals newly described bioactive compounds in Citrullus colocynthis (L.) seeds oil extracts. Heliyon (2023).